Key result
Angiopoietin-like protein inhibitors such as evinacumab effectively reduce plasma total cholesterol, triglycerides, and LDL concentrations in patients with atherogenic dyslipidemia and homozygous familial hypercholesterolemia.
Why the study?
Do ANGPTL inhibitors reduce plasma lipid concentrations in patients with atherogenic dyslipidemia and familial hypercholesterolemia?
Do ANGPTL inhibitors reduce plasma lipid concentrations in patients with atherogenic dyslipidemia and familial hypercholesterolemia?
ANGPTL3 inhibitors like evinacumab represent a promising new therapeutic approach for treating severe lipid disorders, particularly homozygous familial hypercholesterolemia and hypertriglyceridemia, by significantly lowering LDL and triglycerides.
May support ANGPTL inhibition in refractory dyslipidemia; leaves open outcome trials.
Angiopoietin-like proteins (ANGPTL) are involved in the regulation of numerous physiological and biochemical processes. ANGPTL3, 4 and 8, which are involved in the regulation of lipoprotein metabolism, are particularly important. ANGPTL3, 4 and 8 have been shown to regulate triglyceride availability depending on the nutritional status of the body. In addition, a deficiency of these proteins has been found to cause hypolipidemia (reduction of all lipid fractions). Increases in ANGPTL3, 4 and 8 appear to be associated with cardiovascular risk. Animal studies indicate that the use of ANGPTL3 (evinacumab) inhibitors significantly reduces plasma total cholesterol, triglycerides and low-density lipoprotein concentrations. The use of evinacumab in clinical trials also led to the normalization of plasma lipid concentrations in patients with atherogenic dyslipidemia and homozygous familial hypercholesterolemia. The results of these studies indicate that evinacumab may in the future be used in the treatment of lipid disorders, especially those with hypertriglyceridemia.
No takes yet. Share an insight, caveat, or question.
Surma et al. (2021) conducted a review in Atherogenic dyslipidemia and familial hypercholesterolemia. Angiopoietin-like protein inhibitors (evinacumab and ANGPTL3-LRx) was evaluated. Angiopoietin-like protein inhibitors such as evinacumab effectively reduce plasma total cholesterol, triglycerides, and LDL concentrations in patients with atherogenic dyslipidemia and homozygous familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: